In its latest report on brand patent settlements with generic competitors, the U.S. Federal Trade Commission (FTC) found that, despite an increase in the number of final Hatch-Waxman patent settlements in fiscal 2016, significantly fewer settlements included reverse payments that are likely to be anticompetitive.